# CAN020

Source: https://onco.cc/drugs/can020/  
OnCo record `can020` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CAN020 is an experimental drug designed to carry chemotherapy to cancer cells. Its published evidence is from laboratory and animal studies.

## Summary

AACR Drug Discovery and Development 2026 abstract A014 describes CAN020 with TOP1 and PARP inhibitor payloads. Cell and xenograft findings support a DNA-damage and repair-inhibition strategy. Breast, ovarian and gastric tumor models were tested. The authors propose advancement to phase I; that proposal is not evidence of trial initiation or human benefit.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-10-06
- Tags: evidence:preclinical
- Modality: ADC
- Mechanism: TROP2-directed ADC carrying a topoisomerase I inhibitor and a PARP inhibitor on a cleavable StarLinker platform.
- Payload: TOP1 inhibitor plus PARP inhibitor

## Sources

- Publisher abstract: https://doi.org/10.1158/1557-3265.d32026-a014

## Connected records

- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Dual-payload ADC](https://onco.cc/technologies/dual-payload-adc/)
- targets: [TROP2](https://onco.cc/targets/trop2/)

---
JSON: https://onco.cc/api/v1/entities/can020.json